AstraZeneca PLC, the British-Swedish pharmaceutical giant, is facing a securities class action lawsuit in the US. The action alleges that the company misled investors about its business practices in China.
The lawsuit, filed in the US District Court for the Central District of California, claims that AstraZeneca made false and
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day